Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Last updated: March 19, 2024
Sponsor: Howard S. Hochster, MD
Overall Status: Active - Recruiting

Phase

2

Condition

Colon Cancer

Colorectal Cancer

Treatment

NBT-NM108

Clinical Study ID

NCT05296681
072201
Pro2022000222
  • Ages > 18
  • All Genders

Study Summary

This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a high dietary fiber formula that is developed based on research findings that have shown that high fiber diets can help maintain healthy bacteria in the gut and improve gut function. Giving NBT-NM108 to patients with colon cancer receiving chemotherapy may help relieve or lessen diarrhea symptoms and lead to improved tolerance of the chemotherapy drug, irinotecan.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Biopsy proven and metastatic colon cancer

  • Candidate for Second-line or later line therapy with irinotecan-based chemotherapy regimen with starting dose of irinotecan at 180 mg/m2 q2w.

Participants who have had prior irinotecan will be eligible if they are off irinotecan for at least three months and stools have returned to baseline consistency.

  • Performance Status (PS) 0-1

  • Lab values as acceptable for trials: Absolute Neutrophil Count( ANC) >1500/uL; Creatinine < 1.5 x Upper Limit of Normal (ULN); Transaminases < 5x ULN; Bilirubin < 1.5 x ULN; Albumin > 3.0 g/dL

  • No known UGTA1A* genotype

Exclusion Criteria

  • Grade two diarrhea or greater (4-6 movements per day over baseline)

  • Inability to take oral supplements

  • Current antibiotic therapy

  • Baseline grade 3-4 diarrhea Participants with grade two diarrhea should undergo stool evaluation with stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea. They will be eligible if this evaluation shows no infection.

  • History of the following infections and/or disease which could lead to diarrhea:

  • History of prior positive gastrointestinal biopsy, gastrointestinal culture, or stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia, Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea unless fully treated with at least three months normal stool.

  • History of ulcerative colitis, Crohn's disease, celiac sprue (gluten-enteropathy), chronic pancreatitis, malabsorption, or any other gastrointestinal disease associated with diarrhea.

Study Design

Total Participants: 42
Treatment Group(s): 1
Primary Treatment: NBT-NM108
Phase: 2
Study Start date:
May 03, 2022
Estimated Completion Date:
July 01, 2025

Study Description

PRIMARY ENDPOINT:

Dose Intensity of Irinotecan administered (mg/m2/week)

SECONDARY ENDPOINTS:

  1. Reduction in % Patients Needing Dose Modification for Diarrhea

  2. Toxicity Grade of diarrhea

  3. Response Rate

  4. Time to Progression-free survival

EXPLORATORY ENDPOINTS:

  1. 16S rRNA gene sequencing to reveal changes of the gut microbiota including institution of foundation guilds and restoration of healthy microbiome

  2. Short chain fatty acids analysis (promotion of acetic and butyric acid production)

  3. Markers for gut inflammation such as fecal lipocalin 2

  4. Gut barrier function test to see if the restoration of healthier gut microbiota would improve gut barrier function.

Connect with a study center

  • Trinitas Hospital and Comprehensive Cancer Center

    Elizabeth, New Jersey 07202
    United States

    Site Not Available

  • Robert Wood Johnson University Hospital, Hamilton

    Hamilton, New Jersey 08690
    United States

    Active - Recruiting

  • Monmouth Medical Center

    Lakewood, New Jersey 08701
    United States

    Active - Recruiting

  • RWJBarnabas Health - Monmouth Medical Center Southern Campus

    Lakewood, New Jersey 08701
    United States

    Active - Recruiting

  • Cooperman Barnabas Medical Center

    Livingston, New Jersey 07039
    United States

    Active - Recruiting

  • Robert Wood Johnson University Hospital

    New Brunswick, New Jersey 08901
    United States

    Active - Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey 08903
    United States

    Active - Recruiting

  • Newark Beth Israel Medical Center

    Newark, New Jersey 07112
    United States

    Active - Recruiting

  • The Cancer Center

    Newark, New Jersey 07103
    United States

    Active - Recruiting

  • Robert Wood Johnson University Hospital, Somerset

    Somerville, New Jersey 08876
    United States

    Active - Recruiting

  • Community Medical Center

    Toms River, New Jersey 08753
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.